questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vincristine
Vincristine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Triple Negative Breast Neoplasms
Diagnostic
2
Vincristine
Cancer
Diagnostic
Tests de laboratoire
Imagerie médicale
Vincristine
Symptômes
2
Effets secondaires
Neuropathie
Vincristine
Douleur
Neuropathie
Vincristine
Prévention
2
Prévention
Effets secondaires
Vincristine
Évaluation médicale
Vincristine
Préparation au traitement
Traitements
2
Chimiothérapie
Vincristine
Prednisone
Administration intraveineuse
Vincristine
Chimiothérapie
Complications
2
Complications
Infections
Vincristine
Problèmes cardiaques
Vincristine
Surveillance médicale
Facteurs de risque
2
Facteurs de risque
Neuropathie
Vincristine
Antécédents médicaux
Vincristine
Neurologie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vincristine : Questions médicales les plus fréquentes",
"headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-27",
"dateModified": "2025-02-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vincristine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vincristine",
"alternateName": "Vincristine",
"code": {
"@type": "MedicalCode",
"code": "D014750",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wenjian Yang",
"url": "https://questionsmedicales.fr/author/Wenjian%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA."
}
},
{
"@type": "Person",
"name": "Deqing Pei",
"url": "https://questionsmedicales.fr/author/Deqing%20Pei",
"affiliation": {
"@type": "Organization",
"name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA."
}
},
{
"@type": "Person",
"name": "Cheng Cheng",
"url": "https://questionsmedicales.fr/author/Cheng%20Cheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA."
}
},
{
"@type": "Person",
"name": "William E Evans",
"url": "https://questionsmedicales.fr/author/William%20E%20Evans",
"affiliation": {
"@type": "Organization",
"name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA."
}
},
{
"@type": "Person",
"name": "Richard H Ho",
"url": "https://questionsmedicales.fr/author/Richard%20H%20Ho",
"affiliation": {
"@type": "Organization",
"name": "Vanderbilt University Medical Center, Nashville, TN."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Mammographic and ultrasonographic features of triple-negative breast cancer compared with non-triple-negative breast cancer.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35976611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40477-022-00709-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer.",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37394589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s12276-023-01030-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37356327",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.05.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Management of triple negative breast cancer in a centenarian.",
"datePublished": "2022-06-02",
"url": "https://questionsmedicales.fr/article/35652566",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cnr2.1642"
}
},
{
"@type": "ScholarlyArticle",
"name": "The treatment landscape of triple-negative breast cancer.",
"datePublished": "2024-08-29",
"url": "https://questionsmedicales.fr/article/39210220",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12032-024-02456-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vincristine",
"item": "https://questionsmedicales.fr/mesh/D014750"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vincristine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vincristine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vincristine",
"description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vincristine",
"description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vincristine",
"description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vincristine",
"description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vincristine",
"description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vincristine",
"description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?",
"url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Triple+Negative+Breast+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vincristine est-elle utilisée dans le diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vincristine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la vincristine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent neuropathie, constipation, et fatigue."
}
},
{
"@type": "Question",
"name": "La vincristine cause-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vincristine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations avant le traitement par vincristine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une évaluation médicale complète est recommandée avant le traitement."
}
},
{
"@type": "Question",
"name": "Avec quels médicaments la vincristine est-elle souvent combinée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment la vincristine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vincristine est administrée par voie intraveineuse, généralement en cycle."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vincristine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "La vincristine peut-elle causer des problèmes cardiaques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables de la vincristine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 21/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
3 publications dans cette catégorie
Affiliations :
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
3 publications dans cette catégorie
Affiliations :
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
3 publications dans cette catégorie
Affiliations :
Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
3 publications dans cette catégorie
Affiliations :
Vanderbilt University Medical Center, Nashville, TN.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.
Publications dans "Vincristine" :
2 publications dans cette catégorie
Affiliations :
The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
Publications dans "Vincristine" :
To evaluate and compare the mammographic and ultrasonographic features of TNBC with non-TNBC....
A retrospective review of 193 invasive breast cancer patients (TNBC = 32 and non-TNBC = 161) was collected from January 2014 to June 2019. The imaging features were reviewed according to the 5th editi...
Mass without calcifications was the most mammographic feature of TNBC (22 of 32, 68.8%) and more commonly found in TNBC than in non-TNBC (p = 0.007). The irregular shape (19 of 28, 67.9%) and indistin...
TNBC has distinct imaging features compared to non-TNBC. The imaging features on mammography combined with ultrasonography can be used to detect and differentiate this subtype from other breast cancer...
Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine carcinoma with triple negative immunohistochemical results (TNAC), which has been treated as triple...
Triple-negative breast cancer (TNBC) is associated with a high risk of breast cancer-specific mortality (BCSM). Estimating the risk of BCSM and non-BCSM in TNBC would aid clinical decision-making. We ...
Using Surveillance, Epidemiology, and End Results (SEER), we created an interactive tool that provides a nonparametric estimate of the cumulative risk of BCSM and non-BCSM between years 0 and 7 from d...
We included 37,293 women with TNBC diagnosed during 2010-2017. Most patients were White (71.9%) and aged 50-69 years (51.3%). Most tumour characteristics were high-grade (78.6%), T2 (42.4%), and N0 (6...
ESTIMATE-TN is an interactive tool for TNBC that can be used to integrate population-based risks of BCSM and non-BCSM based on patient and tumour characteristics, facilitating our understanding of com...
There is limited clinical data to guide treatment for elderly patients with triple-negative breast cancer (TNBC). In the case of centenarians, there is almost no data for this age group. The diagnosis...
We present the case of a 102-year-old patient who was diagnosed with TNBC. Although our initial plan was observation, the tumor growth rate and the pain it caused resulted in us offering a right total...
Morbidity and mortality are higher in TNBC patients, and treatments are more limited, especially in elderly patients who may not be able to tolerate chemotherapy or surgery. As a result, management of...
Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to ...
Amplification of chromosome 9p24.1 targeting PD-L1, PD-L2, and JAK2 (PDJ amplicon) is present in subsets of triple negative breast cancers (TNBCs) and is associated with poor clinical outcomes. Howeve...
Triple-negative breast cancer (TNBC) has been conventionally associated with poor prognosis, as a result of limited therapeutic options. In the early setting, prognosis is informed by clinical-patholo...
For patients at higher risk, effective postneoadjuvant treatments are of paramount importance to address a high clinical need. Postneoadjuvant risk-adapted treatments have demonstrated to improve surv...
Patients at high risk have indication for adjuvant treatment intensification, informed by baseline clinical, pathological or molecular factors (type 1 approach), on the presence, extent and molecular ...
Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity...
Immunotherapy approaches for TNBC have been diversified in recent years, with breakthroughs in the treatment of this entity. Research on immune checkpoint inhibitors (ICIs) has made it possible to ide...
This review provides insights into the approaches used to overcome drug resistance in immunotherapy, and explores the directions of immunotherapy development in the treatment of TNBC....
The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metast...
The risk factors for breast cancer have been defined in several studies but there is deficient data for specific subtypes. We report here the pathological characteristics of a breast cancer cohort and...